These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38715031)

  • 1. Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII in a novel, longitudinal, multicenter disease monitoring program.
    Giugliani R; Gonzalez-Meneses A; Scarpa M; Burton B; Wang R; Martins E; Oussoren E; Hennermann JB; Chabrol B; Grant CL; Sun A; Durand C; Hetzer J; Malkus B; Marsden D; Merritt Ii JL
    Orphanet J Rare Dis; 2024 May; 19(1):189. PubMed ID: 38715031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII.
    Lau HA; Viskochil D; Tanpaiboon P; Lopez AG; Martins E; Taylor J; Malkus B; Zhang L; Jurecka A; Marsden D
    Mol Genet Metab; 2022 May; 136(1):28-37. PubMed ID: 35331634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII.
    Cadaoas J; Boyle G; Jungles S; Cullen S; Vellard M; Grubb JH; Jurecka A; Sly W; Kakkis E
    Mol Genet Metab; 2020 May; 130(1):65-76. PubMed ID: 32192868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII.
    Wang RY; da Silva Franco JF; López-Valdez J; Martins E; Sutton VR; Whitley CB; Zhang L; Cimms T; Marsden D; Jurecka A; Harmatz P
    Mol Genet Metab; 2020 Mar; 129(3):219-227. PubMed ID: 32063397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials.
    Qi Y; McKeever K; Taylor J; Haller C; Song W; Jones SA; Shi J
    Clin Pharmacokinet; 2019 May; 58(5):673-683. PubMed ID: 30467742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vestronidase Alfa: A Review in Mucopolysaccharidosis VII.
    McCafferty EH; Scott LJ
    BioDrugs; 2019 Apr; 33(2):233-240. PubMed ID: 30848434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease.
    Harmatz P; Whitley CB; Wang RY; Bauer M; Song W; Haller C; Kakkis E
    Mol Genet Metab; 2018 Apr; 123(4):488-494. PubMed ID: 29478819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient.
    Fox JE; Volpe L; Bullaro J; Kakkis ED; Sly WS
    Mol Genet Metab; 2015 Feb; 114(2):203-8. PubMed ID: 25468648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label phase 1/2 study of vestronidase alfa for mucopolysaccharidosis VII.
    Jones S; Coker M; López AG; Sniadecki J; Mayhew J; Hensman P; Jurecka A
    Mol Genet Metab Rep; 2021 Sep; 28():100774. PubMed ID: 34136357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucopolysaccharidosis type VII (Sly syndrome) - What do we know?
    Grant CL; López-Valdez J; Marsden D; Ezgü F
    Mol Genet Metab; 2024 Mar; 141(3):108145. PubMed ID: 38301529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course of sly syndrome (mucopolysaccharidosis type VII).
    Montaño AM; Lock-Hock N; Steiner RD; Graham BH; Szlago M; Greenstein R; Pineda M; Gonzalez-Meneses A; Çoker M; Bartholomew D; Sands MS; Wang R; Giugliani R; Macaya A; Pastores G; Ketko AK; Ezgü F; Tanaka A; Arash L; Beck M; Falk RE; Bhattacharya K; Franco J; White KK; Mitchell GA; Cimbalistiene L; Holtz M; Sly WS
    J Med Genet; 2016 Jun; 53(6):403-18. PubMed ID: 26908836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population.
    Haller C; Song W; Cimms T; Chen CY; Whitley CB; Wang RY; Bauer M; Harmatz P
    JIMD Rep; 2019 Sep; 49(1):53-62. PubMed ID: 31497482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival.
    Vogler C; Sands MS; Levy B; Galvin N; Birkenmeier EH; Sly WS
    Pediatr Res; 1996 Jun; 39(6):1050-4. PubMed ID: 8725268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent effects of enzyme replacement therapy on skeletal disease progression in mucopolysaccharidosis VII dogs.
    Gawri R; Lau YK; Lin G; Shetye SS; Zhang C; Jiang Z; Abdoun K; Scanzello CR; Jo SY; Mai W; Dodge GR; Casal ML; Smith LJ
    Mol Ther Methods Clin Dev; 2023 Mar; 28():12-26. PubMed ID: 36570425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy.
    Vogler C; Levy B; Galvin NJ; Thorpe C; Sands MS; Barker JE; Baty J; Birkenmeier EH; Sly WS
    Pediatr Res; 1999 Jun; 45(6):838-44. PubMed ID: 10367775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans.
    de Ru MH; van der Tol L; van Vlies N; Bigger BW; Hollak CE; Ijlst L; Kulik W; van Lenthe H; Saif MA; Wagemans T; van der Wal WM; Wanders RJ; Wijburg FA
    J Inherit Metab Dis; 2013 Mar; 36(2):247-55. PubMed ID: 22991166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice.
    Grubb JH; Vogler C; Tan Y; Shah GN; MacRae AF; Sly WS
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8375-80. PubMed ID: 18544647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
    Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
    Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII.
    Huynh HT; Grubb JH; Vogler C; Sly WS
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):17022-7. PubMed ID: 23027951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prenatal diagnosis of mucopolysaccharidosis type VII facilitating treatment in neonatal period.
    Chandler NJ; Ramachandran V; Beesley C; Otigbah C; Davison J; Ashraf T
    Prenat Diagn; 2023 Nov; 43(12):1567-1569. PubMed ID: 37964423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.